Justices look for line to draw in drug preemption case 
By:
Kimberly Atkins
Published: March 20, 2013
Tags: design defect, drug litigation, federal preemption, implied preemption, U.S. Supreme Court
WASHINGTON – Deciding where the preemptive effect of federal rules governing drug manufacturing ends and states’ ability to impose liability on drug makers begins has never been an easy task — not even for the justices of the U.S. Supreme Court.
On Tuesday, the justices wrangled once again over the preemptive reach of the federal Food, Drug and Cosmetic Act in an effort to decide whether the law prevents design defect claims against generic drug manufacturers.
Roche appeals, fights for new Accutane judge
Published: March 11, 2013
Tags: Accutane, birth defects, DRI, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, recusal
Continuing in its efforts to find a new judge for the thousands of Accutane cases pending in New Jersey state court, Hoffman-La Roche filed notice to appeal a decision by presiding Judge Carol E. Higbee not to recuse herself in the case.
N.J. judge refuses to recuse herself from Accutane cases
Published: March 4, 2013
Tags: Accutane, birth defects, DRI, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, recusal, suicide
The state judge overseeing Accutane mass tort litigation in New Jersey has denied Hoffmann- La Roche’s motion asking that she recuse herself.
Mass. jury awards $63M for child’s reaction to Motrin
By:
Correy Stephenson
Published: March 1, 2013
Tags: Children’s Motrin, consumer protection, drug litigation, failure to warn, FDA, Food and Drug Administration, Johnson & Johnson, Motrin, preemption, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
A Massachusetts jury awarded $63 million to a teenaged girl and her parents after the girl suffered an adverse reaction to Children’s Motrin that left her scarred and blind, with permanent brain and lung damage.
And the award may increase.
Propecia’s sexual side effects may be ‘irreversible,’ report says
Published: February 7, 2013
Tags: ADHD, Daytrana, drug litigation, FDA, Food and Drug Administration, Institute for Safe Medication Practices, multidistrict litigation, Noven Therapeutics, product liability, Propecia, Proscar, QuarterWatch
Sexual side effects experienced by men taking the hair-loss drug Propecia may be permanent, according to a new report by a drug industry watchdog.
Pfizer avoids Chantix bellwether trial with settlement
Published: January 28, 2013
Tags: Chantix, drug litigation, multidistrict litigation, Pfizer, suicide
Pfizer has avoided a bellwether trial scheduled to begin this month in the Chantix multidistrict litigation by settling with an Alabama man who claimed he became suicidal after taking the smoking-cessation drug.
Generic drug user can sue brand-name manufacturer
Published: January 16, 2013
Tags: drug litigation, failure to warn, fraudulent misrepresentation, Reglan
State law allows the user of a generic drug to sue the maker of the name-brand drug for fraudulent misrepresentation, the Alabama Supreme Court has ruled in answering a certified question from a U.S. District Court.
Hoffmann-La Roche asks for Accutane judge’s recusal
Published: December 28, 2012
Tags: Accutane, drug litigation, Hoffmann-La Roche, inflammatory bowel disease, mass tort litigation, recusal
Drug maker Hoffmann- La Roche has asked for the recusal of the New Jersey judge overseeing the Accutane mass tort litigation, asserting that Judge Carol E. Higbee is siding unfairly with plaintiffs who allege injuries from the acne drug.
Dialysis product litigation proceeds amid recall
By:
Sylvia Hsieh
Published: December 19, 2012
Tags: dialysis, drug litigation, FDA, Food and Drug Administration, Fresenius Medical Care, Granuflo, statute of limitations
Litigation over the dialysis product GranuFlo is underway, months after the Food and Drug Administration recalled the product amid concerns that it can cause cardiac arrhythmia, which in some cases has led to sudden death.
Supreme Court won’t hear fen-phen lawyer’s appeal
Published: December 13, 2012
Tags: American Home Products, diet drugs, drug litigation, fen-phen, product liability, U.S. Supreme Court, wire fraud
The U.S. Supreme Court will not review the conviction of a disbarred Kentucky attorney who attempted to defraud clients of their share of a $200 million settlement compensating those injured by the diet drug fen-phen.
